In a report released today, Joshua Schimmer from Evercore ISI maintained a Hold rating on Bluebird Bio (BLUE – Research Report), with a price target of $86.00. The company’s shares closed last Monday at $79.42, close to its 52-week low of $71.42.
According to TipRanks.com, Schimmer is a 5-star analyst with an average return of 11.3% and a 53.4% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Alexion Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluebird Bio with a $116.63 average price target, representing a 43.6% upside. In a report issued on December 3, Morgan Stanley also maintained a Hold rating on the stock with a $100.00 price target.
The company has a one-year high of $163.43 and a one-year low of $71.42. Currently, Bluebird Bio has an average volume of 935.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217.